Ralph Defronzo
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1851408843
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by AstraZeneca at 37.4% of the total. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 509 payments — averaging $1728.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$329K
- Corcept Therapeutics$168K
- Novo Nordisk$150K
- Hikma Pharmaceuticals USA$67K
- Regeneron$34K
- Alnylam Pharmaceuticals Inc.$21K
- plus $112K from 21 others
Across 18 payments — averaging $215,553 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.5M
- Merck$965K
- Janssen Research & Development, LLC$237K
- Amgen$145K
- Boehringer Ingelheim$26K
What the payments were for
- Consulting fees$254,52529%
- Speaking & faculty fees$489,68856%
- Travel & lodging$122,90814%
- Food & beverage$12,4851%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 235 | $328,646 |
| Corcept Therapeutics | 73 | $167,596 |
| Novo Nordisk | 87 | $150,000 |
| Hikma Pharmaceuticals USA | 19 | $66,846 |
| Regeneron | 37 | $34,135 |
| Alnylam Pharmaceuticals Inc. | 3 | $20,880 |
| Johnson & Johnson | 6 | $14,375 |
| Novo Nordisk AS | 7 | $14,085 |
| Pfizer | 4 | $12,800 |
| GSK | 4 | $9,833 |
| Boehringer Ingelheim (phil.) Inc. | 2 | $9,060 |
| Renalytix AI, Inc. | 3 | $8,688 |
| AbbVie | 1 | $8,250 |
| Bayer | 8 | $8,036 |
| Boehringer Ingelheim | 3 | $5,567 |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | 2 | $5,225 |
| Astrazeneca AB | 1 | $3,600 |
| Azurity Pharmaceuticals, Inc. | 2 | $3,120 |
| Dr.reddy's Laboratories,inc. | 1 | $2,503 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $2,490 |
| Boehringer Ingelheim RCV GmbH & Co KG | 1 | $2,471 |
| Amgen | 3 | $868 |
| Xeris Pharmaceuticals, Inc. | 1 | $133 |
| Medtronic | 1 | $125 |
| Intercept Pharmaceuticals, Inc. | 1 | $124 |
| Madrigal Pharmaceuticals | 1 | $92 |
| Eli Lilly | 1 | $76 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$879,625 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Other endocrinology, diabetes & metabolism in San Antonio
- Firas AkhrassSan Antonio$801K
- Carolina Solis-HerreraSan Antonio$600K
- Jeannie BaqueroSan Antonio$573K
- Kathleen HandsSan Antonio$223K
- Shahid AzizSan Antonio$173K
- William TrigosoSan Antonio$170K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.